Mr. Abhijit Barve
President , R&D
Dr. Abhijit Shrikrishna Barve, M.D., Ph.D., M.B.A., served as the President of Research & Development at Biocon Limited since November from 2010 to July 2015. Dr. Barve served as the Chief Operating Officer of Clinigene at Biocon Limited since May 1, 2010. Dr. Barve was with Astellas Pharma Inc. in Deerfield, IL, USA prior to Clinigene.
He has over 15 years of global drug development experience covering preclinical, early and late stage clinical development, clinical operations, regulatory and safety functions. During this timeframe, he has filed at least a dozen IND applications and has led the team that successfully negotiated the original and expanded labeling for Vaprisol. He has extensively interacted with various divisions of the FDA and also with EMEA and PMDA. At Astellas, he headed their Global Cardiac Safety Task Force.
His clinical trial experiences span across the globe, where he has successfully managed diverse global teams in a highly matrix organization across multiple therapeutic areas. He joined Fujisawa Research Institute of America as Asst. Medical Director in 1999 and was Medical Director at Astellas Pharma (formerly Fujisawa) until 2008.
In 2008, he became Senior Director, Business Development at Astellas responsible for strategic, financial and scientific assessment of business opportunities in the areas of CNS, Pain and Oncology. In 2009, he returned to Astellas R&D as Global Development Project Leader accountable for overall development for CNS programs, the position he held until he left Astellas in 2010. He is Member of multiple prestigious scientific organizations.
Dr. Barve trained at Tilak Municipal Medical College & Hospital and Seth G.S Medical College & KEM Hospital, where he received his MBBS and MD degrees in 1992 and 1995, respectively. He received his PhD in Pharmacy from Dep, Biopharmaceutical sciences at university of Illinois at Chicago in 1999, where he studied cardiovascular Pharmacology of hemoglobin based oxygen carriers as therapeutic agents. In 2007, he received MBA in Finance, Entrepreneurship, and Strategy from the university Chicago, Booth school of Business.